Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Fiasp (insulin aspart)
pCPA File Number:
21023
Negotiation Status:
Concluded without agreement
Indication(s):
Diabetes Mellitus, Type 1 & 2
Sponsor/Manufacturer:
Novo Nordisk Canada Inc.
CADTH Project Number:
Not Applicable
pCPA Engagement Letter Issued:
2018-03-16
Negotiation Process Concluded:
2019-01-30